

Margus Viigimaa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/275316/publications.pdf>

Version: 2024-02-01

119
papers

49,075
citations

66315

42
h-index

24961

109
g-index

125
all docs

125
docs citations

125
times ranked

45164
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). <i>Clinical Nutrition</i> , 2021, 40, 255-276.	2.3	75
2	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. <i>European Heart Journal</i> , 2021, 42, 17-96.	1.0	830
3	Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use. <i>Journal of Medical Biochemistry</i> , 2021, 40, 167-172.	0.7	6
4	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	4.3	19
5	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	1.6	39
6	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	6.3	142
7	Assessment of Associations Between Arterial Mechanical Properties and Biochemical Blood Markers for Early Detection of Atherosclerosis. <i>IFMBE Proceedings</i> , 2021, , 121-129.	0.2	1
8	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
9	Digital Health in Cardiology: The Estonian Perspective. <i>Cardiology</i> , 2020, 145, 21-26.	0.6	6
10	Construction of gender-specific regression models for aortic length estimation based on computed tomography images. <i>Health and Technology</i> , 2020, 10, 679-687.	2.1	2
11	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020, 41, 12-85.	1.0	690
12	Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , 2020, 38, 1220-1234.	0.3	25
13	Hypertension and Reproduction. <i>Current Hypertension Reports</i> , 2020, 22, 29.	1.5	14
14	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	3.1	17
15	Disclosing Pharmacogenetic Feedback of Caffeine via eHealth Channels, Assessment of the Methods and Effects to Behavior Change: A Pilot Study. <i>Frontiers in Digital Health</i> , 2020, 2, 567656.	1.5	0
16	Macrovascular Complications of Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2020, 18, 110-116.	0.8	177
17	Aortic Augmentation Index is Dependent on Bodyside in Healthy Young Subjects. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 375-382.	1.0	0
18	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207

#	ARTICLE	IF	CITATIONS
19	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
20	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
21	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
22	Psychosocial Factors and Personality Traits and the Prevalence of Arterial Hypertension Among 35- and 55-Year-Old Men and Women in Sweden and Estonia: a SWESTONIA Longitudinal Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 475-482.	1.0	2
23	New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia. <i>Current Pharmaceutical Design</i> , 2019, 24, 3599-3604.	0.9	6
24	The Metabolic Profile of Stable Ischemic Heart Disease by Serum 1H NMR. <i>Applied Magnetic Resonance</i> , 2019, 50, 527-539.	0.6	1
25	The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2019, 24, 5491-5499.	0.9	6
26	Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22416.	0.9	23
27	Stroke volume assessment by impedance cardiography: Comparative analysis with transthoracic echocardiography. <i>IFMBE Proceedings</i> , 2018, , 398-401.	0.2	0
28	Pulse wave velocity and its gender-related associations with cardiovascular risk factors in a high cardiovascular risk population. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2018, 3, 99-105.	0.5	5
29	Second derivative photoplethysmographic signal analysis of differences between fingers in healthy subjects. , 2018, , .		0
30	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.4	163
31	Rapid socio-economic changes, psychosocial factors and prevalence of hypertension among men and women aged 55 years at baseline in Estonia: a 13-year follow-up study. <i>Blood Pressure</i> , 2018, 27, 351-357.	0.7	1
32	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
33	Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study. <i>Blood Pressure</i> , 2018, 27, 368-375.	0.7	4
34	Investigation of photoplethysmographic signal augmentation index estimation differences between fingers. <i>IFMBE Proceedings</i> , 2018, , 819-822.	0.2	2
35	Prevalence of cardiovascular disease risk factors in Tallinn, Estonia. <i>Medicina (Lithuania)</i> , 2017, 53, 268-276.	0.8	6
36	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. <i>Journal of Hypertension</i> , 2016, 34, 393-396.	0.3	26

#	ARTICLE	IF	CITATIONS
37	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.0	71
38	Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients. <i>Journal of Diabetes</i> , 2016, 8, 398-404.	0.8	24
39	Lipoprotein-associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	44
40	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 839-846.	0.8	39
41	A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. <i>Journal of Hypertension</i> , 2015, 33, 2534-2545.	0.3	23
42	Pulse wave registration from radial artery using photoplethysmographic method. , 2015, 2015, 6425-8.		0
43	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
44	Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans. <i>PLoS ONE</i> , 2015, 10, e0119752.	1.1	64
45	Management of erectile dysfunction in hypertension: Tips and tricks. <i>World Journal of Cardiology</i> , 2014, 6, 908.	0.5	46
46	Photoplethysmographic signal waveform index for detection of increased arterial stiffness. <i>Physiological Measurement</i> , 2014, 35, 2027-2036.	1.2	45
47	Impact of smoking: All-cause and cardiovascular mortality in a cohort of 55-year-old Swedes and Estonians. <i>Scandinavian Journal of Public Health</i> , 2014, 42, 780-785.	1.2	7
48	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014, 23, 3-16.	0.7	565
49	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.3	39
50	Prevalence and determinants of hypertension in Estonian adults. <i>Scandinavian Journal of Public Health</i> , 2014, 42, 504-510.	1.2	12
51	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiología</i> , 2014, 67, 136.e1-136.e56.	0.6	15
52	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	13.9	467
53	Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS). <i>Medicina (Lithuania)</i> , 2014, 50, 44-53.	0.8	6
54	The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injury in atherosclerosis and diabetes. <i>Molecular and Cellular Biochemistry</i> , 2014, 395, 241-252.	1.4	51

#	ARTICLE	IF	CITATIONS
55	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. <i>Journal of Hypertension</i> , 2014, 32, 1888-1897.	0.3	65
56	Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients. <i>Blood Pressure</i> , 2013, 22, 362-370.	0.7	7
57	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
58	Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. <i>Nature Genetics</i> , 2013, 45, 145-154.	9.4	675
59	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Española De Cardiología</i> , 2013, 66, 880.e1-880.e64.	0.6	24
60	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	0.7	355
61	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
62	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.3	4,251
63	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013, 31, 1925-1938.	0.3	789
64	The effect of local cold and warm exposure on index finger photoplethysmographic signal waveform. , 2013, 2013, 2300-3.		3
65	New Photoplethysmographic Signal Analysis Algorithm for Arterial Stiffness Estimation. <i>Scientific World Journal</i> , The, 2013, 2013, 1-9.	0.8	52
66	Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. <i>Cardiovascular Therapeutics</i> , 2012, 30, 61-74.	1.1	15
67	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) *Developed with the special contribution of the European Association for Cardiovascular Prevention	1.0	5,247
68	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq0 0 Q rgBT /Overlock 10 T	1.0	79
69	Prevention & Rehabilitation (EACPR). [Eur Heart J] 2012;33:1635-1701, doi: 10.1093/eurheartj/ehs092]. <i>European Heart Journal</i> , 2012, 33, 2126-2126.		0
70	Sexual Function in Untreated and Treated Hypertension. , 2012, , 389-398.		0
71	Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. <i>Nature</i> , 2011, 478, 103-109.	13.7	1,855
72	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767
72	Hypertension and sexual dysfunction: time to act. <i>Journal of Hypertension</i> , 2011, 29, 403-407.	0.3	66

#	ARTICLE	IF	CITATIONS
73	Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. <i>European Heart Journal</i> , 2011, 32, 218-225.	1.0	70
74	Blood Pressure Loci Identified with a Gene-Centric Array. <i>American Journal of Human Genetics</i> , 2011, 89, 688-700.	2.6	159
75	Cholesterol-rich low density lipoproteins are also more oxidized. <i>Molecular and Cellular Biochemistry</i> , 2011, 355, 187-191.	1.4	13
76	Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity. <i>Combination Products in Therapy</i> , 2011, 1, 1.	1.1	3
77	HYPEST study: profile of hypertensive patients in Estonia. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 55.	0.7	9
78	Novel polymorphic AluYb8 insertion in the WNK1 gene is associated with blood pressure variation in Europeans. <i>Human Mutation</i> , 2011, 32, 806-814.	1.1	23
79	Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. <i>Clinical Biochemistry</i> , 2011, 44, 627-634.	0.8	3
80	Cardiovascular disease risk factors in homeless people. <i>Upsala Journal of Medical Sciences</i> , 2011, 116, 200-207.	0.4	8
81	Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. <i>Human Molecular Genetics</i> , 2011, 20, 2273-2284.	1.4	168
82	Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 262-270.	0.9	12
83	Setting-up a Blood Pressure and Vascular Protection Clinic: Requirements of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2010, 28, 1780-1781.	0.3	11
84	Agreement within Europe about antihypertensive treatment and education – results from the European Society of Hypertension questionnaire. <i>Journal of Hypertension</i> , 2010, 28, 1593-1594.	0.3	2
85	Interrelation between Malonyl Dialdehyde-Dependent Modification and Cholesterol Content in Low-Density Lipoproteins. <i>Bulletin of Experimental Biology and Medicine</i> , 2010, 149, 184-186.	0.3	1
86	Hypervariable intronic region in NCX1 is enriched in short insertion-deletion polymorphisms and showed association with cardiovascular traits. <i>BMC Medical Genetics</i> , 2010, 11, 15.	2.1	8
87	Efficacy of Switching from Statin Monotherapy to Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients Analyzed by Baseline LDL-C. <i>Journal of Clinical Lipidology</i> , 2010, 4, 204-205.	0.6	0
88	Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency. <i>Journal of Clinical Lipidology</i> , 2010, 4, 207-208.	0.6	0
89	Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. <i>Lipids in Health and Disease</i> , 2010, 9, 127.	1.2	6
90	Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. <i>Blood Pressure</i> , 2010, 19, 164-168.	0.7	36

#	ARTICLE	IF	CITATIONS
91	An experimental measurement complex for probable estimation of arterial stiffness. , 2010, 2010, 194-7.		9
92	Polymorphisms in the WNK1 Gene Are Associated with Blood Pressure Variation and Urinary Potassium Excretion. PLoS ONE, 2009, 4, e5003.	1.1	43
93	Targeting 160 Candidate Genes for Blood Pressure Regulation with a Genome-Wide Genotyping Array. PLoS ONE, 2009, 4, e6034.	1.1	98
94	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension, 2009, 27, 2121-2158.	0.3	1,236
95	Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Human Molecular Genetics, 2009, 18, 2288-2296.	1.4	170
96	Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International Journal of Clinical Practice, 2009, 63, 547-559.	0.8	62
97	Experiences of Telemedicine-Aided Hypertension Control in the Follow-Up of Finnish Hypertensive Patients. Telemedicine Journal and E-Health, 2009, 15, 764-769.	1.6	7
98	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure, 2009, 18, 308-347.	0.7	351
99	European Society Of Hypertension Excellence Centres March 7, 2009. Blood Pressure, 2009, 18, 157-164.	0.7	0
100	N-acetyltransferase 8, a positional candidate for blood pressure and renal regulation: resequencing, association and in silico study. BMC Medical Genetics, 2008, 9, 25.	2.1	23
101	New ESH Hypertension Excellence centers approved. Blood Pressure, 2008, 17, 178-180.	0.7	1
102	SLC2A9 Is a High-Capacity Urate Transporter in Humans. PLoS Medicine, 2008, 5, e197.	3.9	305
103	Assessment of Pulse Wave Velocity and Augmentation Index in different arteries in patients with severe coronary heart disease. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 1703-6.	0.5	9
104	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
105	ESH Hypertension Excellence Centres: a new strategy to combat an old foe. Journal of Hypertension, 2007, 25, 1744-1748.	0.3	1
106	Risk factor control in treated hypertensives from Estonia and Sweden. Why the difference?. Blood Pressure, 2007, 16, 301-304.	0.7	5
107	Resequencing PNMT in European hypertensive and normotensive individuals: no common susceptibility variants for hypertension and purifying selection on intron 1. BMC Medical Genetics, 2007, 8, 47.	2.1	12
108	Daily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period. Journal of Telemedicine and Telecare, 2005, 11, 34-36.	1.4	43

#	ARTICLE	IF	CITATIONS
109	Self-reported compliance of patients receiving antihypertensive treatment: Use of a telemonitoring home care system. <i>Journal of Telemedicine and Telecare</i> , 2003, 9, 65-66.	1.4	15
110	Risk factors for coronary heart disease in 55- and 35-year-old men and women in Sweden and Estonia. <i>Journal of Internal Medicine</i> , 2002, 252, 551-560.	2.7	11
111	A psychosocial comparison of 35- and 55-year-old men and women in Sweden and Estonia: The swestonia cardiovascular risk factor study. <i>International Journal of Behavioral Medicine</i> , 2001, 8, 149-162.	0.8	3
112	Tasosartan and hydrochlorothiazide as combination therapy in the treatment of severe essential hypertension: comparison with enalapril. Tasosartan Study Group. <i>Cardiovascular Drugs and Therapy</i> , 2000, 14, 447-449.	1.3	0
113	The Renin-Angiotensin System in Essential Hypertension: Associations with Cardiovascular Risk. <i>Blood Pressure</i> , 1999, 8, 70-78.	0.7	23
114	The Baltic Atherosclerosis Journal. <i>Clinical Chemistry and Laboratory Medicine</i> , 1999, 37, 841.	1.4	0
115	Effect of ciprofibrate on platelet aggregation in patients with combined hyperlipidemia. <i>Platelets</i> , 1998, 9, 265-267.	1.1	1
116	Platelet Aggregation, Thromboxane A ₂ , Prostacyclin Generation and Platelet Sensitivity to Prostacyclin during the First Month after Myocardial Infarction. <i>Platelets</i> , 1995, 6, 402-407.	1.1	2
117	Antiaggregative Therapy with Acetylsalicylic Acid and Diclofenac in Patients with Acute Myocardial Infarction. <i>Uppsala Journal of Medical Sciences</i> , 1994, 99, 131-138.	0.4	1
118	Antithrombotic effect and reperfusion by low molecular weight heparin in a canine model of coronary artery thrombosis. <i>Japanese Circulation Journal</i> , 1993, 57, 553-557.	1.0	4
119	Synthesis and anti-aggregative activity of novel 1% <i>o</i> -achiral carba-analogues of prostacyclin. <i>European Journal of Medicinal Chemistry</i> , 1992, 27, 155-159.	2.6	5